Form 4: BiomX Inc. Director James E. Flynn Reports Acquisition of Warrants Following Stockholder Approval

James E. Flynn, a director by deputization of BiomX Inc., reports the acquisition of warrants exercisable for 1,611,864 shares of common stock after stockholder approval was obtained.

Summary

• James E. Flynn, a director by deputization of BiomX Inc., filed a Form 4 disclosing the acquisition of warrants.
• The warrants, acquired on April 21, 2025, are exercisable for 1,611,864 shares of BiomX Inc. common stock at an exercise price of $0.9306.
• The warrants were originally issued on February 27, 2025, but became exercisable only after stockholder approval, which was obtained on April 21, 2025.
• The warrants expire on April 21, 2030.
• The warrants are held indirectly through Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P.
• The filing also includes a joint filer information statement listing Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P. and Deerfield Management Company, L.P.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to warrant acquisition following stockholder approval. While insider activity can be a positive signal, this is more of a procedural update.

Positives

• The acquisition of warrants by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and doesn't necessarily reflect broader industry trends. However, it does indicate continued investment interest from Deerfield Management, a significant healthcare investor.

Stakeholder Impact

• The acquisition of warrants could potentially impact shareholders if the warrants are exercised, leading to dilution of existing shares.

Key Dates

Keywords

Form 4, BiomX Inc., Warrants, Deerfield, Beneficial Ownership, James E. Flynn